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GROWTH OF MALIGNANT MELANOMA has
occasionally been shown to be hormone-
dependent. Bodenham & Hale (1972)
administered 32p to patients with meta-
stases of malignant melanoma and meas-
ured the uptake in the metastases and in
control tissues with a Geiger probe. After
a few days, when the uptake curve was
found to be constant, oestrogens were
administered. A change in the uptake
curve was found in 4/26 cases. Two of
these 4 patients were hypophysectomized
and showed remissions for at least 9
months. The 2 others showed regression
after administration of either testosterone
phenylpropionate in a man and ethinyl
oestradiol in a woman. In another report
on 5 patients, a melanoma developed or
became worse after oestrogen administra-
tion (Sadoff et al., 1973). In a preliminary
study regression was reported in 5/44
melanoma patients after treatment with
the anti-oestrogenic progestational drug
6a - methylpregn - 4 - ene - 3,11,20 - trione
(NSC-1 7256; Johnson et al., 1966). Several
authors have reported the influence of
pregnancy on the course of melanoma.
References can be found in the paper of
Shiu et al. (1976) who showed in their study
that with Stage II but not with Stage I
melanoma patients the rate of survival
for 5 years free of disease was significantly
lower in patients who were treated during
pregnancy or who had symptoms of
activation of the skin lesion during a
previous pregnancy, than in those who
were nulliparous or who had no symptoms
ofactivationi during a previous pregnancy.
In contrast to an adverse effect of preg-
nancy stands the remarkable case of a
patient whose melanoma regressed during
successive pregnancies (Boyd, 1957). Re-
cently Shaw et al. (1978) concluded from
a study on a large series of patients that
there may be endocrine influences on the
rate of formation of metastases and the
anatomical distribution of the sites of
primary lesions.
Although hormonal dependency of the
growth rate of metastases has clearly been
shown, it occurs in so few patients that
hormonal treatment ofmelanoma patients
with advanced disease, as is practised in
mammary carcinoma, is not customary.
However, endocrine therapy would be-
come the treatment of choice if it were
possible to select appropriate patients by
some criterion for hormone dependency.
This situation is possible in breast-cancer
patients where specific binding of oestro-
gens to receptor in tumour extract has
been shown to correlate with successful
hormonal treatment (McCuire et al., 1975).
So far, only Fisher et al. (1976) have repor-
ted the detection of oestrogen receptor
activity in the metastases of 16/35 patients
with malignant melanoma.
It is the aim of this paper to report on
the binding activity to oestrogen and
dihydro-testosterone by melanoma meta-
stases, as found with the routine proce-
dures which are in use in our laboratory
for the detection of hormone-receptor
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Hormone-receptor assay
Extracts of the tumour tissues were
prepared asrecommended at theworkshop
in 1972 of the EORTC Breast Cancer Co-
operative Group (1973), using a "micro-
dismembrator" (Braun, Melsungen, Ger-
many). Incubation with the labelled
oestrogen [(6,7-3H) oestradiol-17fl] (E2),
40 Ci/mmol or androgen [5-dihydro (1,2-
3H)-testosterone] (DHT), 48 Ci/mmol was
done at 4°C for about 16 h. The final
concentration of the labelled hormone
was 3 nm. Total proteinwasassayedbythe
biuret reaction. Human serum albumin
was assayed immunologically by single
diffusion using Partigen plates, manufac-
tured by Behring Werke (Germany).
The estimated amount of serum proteins
in the cytosol was calculated by multiply-
ing the albumin concentration by a factor
of 10/6 (assuming an albumin concentra-
tion of 60% in the extracellular protein
contaminants ofthe extracts). The amount
of soluble tissue proteins is then the total
protein amount minus the amount of
serum proteins. Oestrogen and androgen
receptors were determined in the extract
using agar electrophoresis. This technique
has been described in detail by Wagner
(1972). Theelectrophoresis equipmentused
in our study was an exact replica of the
one described in the paper of Wagner.
The electrophoresis separates high-affinity
receptors from sex-hormone binding to
globulin and unbound hormone, since the
former migrates to the anode while the
sex-hormone binding globulin and un-
bound hormone are shifted towards the
cathode. As a control we used heated
cytosol (1 h at 45°C). The difference
between the anodal peaks ofthe unheated
and preheated cytosol was used as a
measure of high-affinity steroid binding
capacity, which was expressed in fmol of
receptor bound per mg tissue protein.
Metastatic excisions
E2 and DHT receptors were determined
in excised metastases of patients with
histologically proven disseminated malig-
nant melanoma. All specimens were frozen
within 1 h and stored at - 70°C before the
extracts were made. Thirty-nine extracts
were assayed within 12 days, and 4 within
4 months. All assays were performed
simultaneously with extracts of breast
cancers.
TheTable showstheresults ofthe assays
on 21 metastases of 17 male and 22 meta-
stases of 17 female patients. E2 receptor
was measurable in 7/31 cutaneous and
1/9 lymphnode metastases, the concentra-
tion in this lymphnode metastasis being
the lowest of all measurable assays. In
the 3 non-skin, non-lymphnode meta-
stases no E2receptorwas detectable. There
is no relationship between the sex of the
patients and the presence ofE2 receptor in
a skin metastasis, and no relationship
between the presence of detectable E2
and DHT receptor. DHT-binding activity
was found in 7/31 cutaneous, 4/9 lymph-
node metastases, and 0/3 non-skin, non-
lymphnode metastases. In one patient
there was DHT activity found in a skin
and a lymphnode metastasis excised at
the same time. In 6 patients both assays
were performed on another metastasis at
another time. In 3 cases the first but not
the second, and in 2 cases the second but
not the first had detectable E2 receptors.
In 2 cases DHT receptor was detectable,
one the first and one the second time.
Thus, in no case was a receptor detectable
on both occasions.
The 2 women with the highest receptor
activity (one with E2, the other with
DHT) had never been pregnant, nor had
they used oral contraceptives. Nearly all
patients in whom receptor activity was
found had progressive disease; only one
man (76/1909) with DHT binding activity
in a removed regional lymphnode meta-
stasis, is still disease-free 3 years later. No
relationship was found between the pre-
sence of receptor and the prognosis of the
disease or the age or sex ofthe patient.
In the 4 instances in which the speci-
mens had to be stored for 4 months, there
were 2 cases where E2 receptor was
detectable (1.1 and 11-6 fmol/mg).
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TABLE
Age
57
41
57
28
61
62
91
76
48
44
33
34
49
38
24
52
47
54
57
65
66
43
45
84
28
62
27
27
28
37
73
62
38
70
33
33
27
56
39
53
Site of Date of
excision excision
Skin 05.07.73
Skin 05.07.73
Skin 28.12.73
Lymph node 28.12.73
Jejunum 07.02.74
Skin 08.04.74
Skin 24.04.75
Lymph node 09.10.75
Skin 24.04.75
Skin 02.06.75
Skin 19.06.75
Lymph node 08.07.75
Skin 17.11.75
Skin 01.12.76
Skin 03.09.75
Skin 17.12.75
Skin 19.12.75
Skin 31.12.75
Skin 23.01.76
Lymph node 04.02.76
Lymph node 15.09.76
Skin 20.07.73
Skin 14.03.74
Skin 23.07.73
Skin 17.06.75
Lymph node 30.11.73
Skin 20.02.74
Lymph node 27.02.74
Breast 13.02.75
Lymph node 18.04.75
Skin 12.08.76
Skin 08.07.75
Skin 17.07.75
Skin 05.08.75
Skin 17.09.75
Lymph node 20.11.75
Skin 17.12.75
Skin 05.03.76
Skin 12.03.76
Skin 12.03.76
Skin 28.07.76
Lung 24.03.76
Skin 01.11.76
Binding of
A
E2 DHT
(fmol/mg cytosol
tissue protein)
030
0 98
13
5.5
8 0
3-8
6 9
1-1
22
11 6
0 6
8-9
11.5
0-38
16 7
0 22
22
1-8
0 72
* Not measurable (< 0 5 fmol E2 and < 0-15 fmol DHT/mg cytosol tissue protein).
Two male patients (71/0288 and 75/
1875) received hormonal treatment after
a high DHT-binding activity had been
found. The first man, 28 years old,
received 3 nig ethinyloestradiol daily for
6 weeks, and thereafter the antitesto-
sterone drug cyproterone acetate, 100 mg
daily, but without any effect on the pro-
gression of the lung and skin metastases.
The other patient, 24 years old, only
received cyproterone acetate in the last
2 weeks of his life, without any effect on
the progression ofthe disease.
This study shows that E2 and DHT
receptors can be present in some melanoma
metastases. According to studies on breast
cancer, E2-binding activity of more than
15-30 fmol/mg cytosol tissue protein is
considered as "receptor-positive". Accord-
ing to this criterion we found only one
Patient
No.
73/0432
73/0432
To. (LDI)
To. (LDI)
72/1398
71/0288
74/0813
74/0813
75/0533
72/2032
75/1413
75/1037
72/2142
72/2142
74/2413
75/2903
75/1875
74/2213
76/0124
76/0142
76/1909
73/1300
73/1300
70/0267
70/0267
73/2138
74/0385
73/0186
75/0191
74/2087
74/2087
73/1469
73/0959
69/0602
73/1773
75/2558
75/1809
75/1809
76/0549
76/0549
72/1880
73/2155
75/0937
Sex
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
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female patient having E2 receptor on at
least one occasion in a skin metastasis.
Although detectable in 20-25% of the
patients the levels are generally too low
to be considered of any relevance to
endocrine treatment. Moreover, in 6 cases
(2 males and 4 females) there was no
consistently detectable receptor present,
while in none ofthem was receptor present
on 2 occasions.
The incidence of E2 positivity in our
study is lower than reported by Fisher et
al. (1976) who found 16/35 patients with
levels higher than 5 fmol/mg cytosol.
Another difference from their findings
concerns the relationship with the sites
of the metastases. While we found E2
receptors virtually only in skin (7/31)
and hardly in lymphnode metastases
(1/9), Fisher etal. (1976) foundaprevalence
for lymphnode metastases (9/18 of lymph
node and 4/12 of skin metastases). In
theirstudy, however, adifferenttechnique,
including the reagent dithiothreitol (DTT)
and analysis of the results by Scatchard
plot was used. DTT has been suggested to
increase the yield of the receptor assay
(McGuire & DeLaGarza, 1973; Ratajczak
& Hahnel, 1976), but other laboratories
(Mester et al., 1970; Braunsberg, 1975;
Keightley et al., 1978) including ours
(unpublished results) have found that this
reagent is not effective. The analysis by
Scatchard plot may lead to erroneous
results in the assay of cytosols where the
contamination with plasma-binding pro-
teins of lower specificity may be consider-
able. A critical discussion of this problem
from which misclassification of receptors
or miscalculation of the dissociation con-
stant (KD) may result, is given by Brauns-
berg (1975). For the present discussion
we would remark that in the quoted study
of Fisher et al. (1976) a constant (KD) as
high as 4*9 x 10-9M was calculated, which
was considered to represent high-affinity
binding. Such a high value, however, may,
according to Braunsberg (1975) and others
(vide McGuire et al., 1975) rather suggest
a low-affinity binding. This could then
explain the higher incidence of E2 recep-
tors in melanoma in the study of Fisher
et al. (1976) when compared to our vir-
tually negative results. In our study no
KD values could be determined, since the
technique used is based on incubation
with a single saturating oestradiol con-
centration. There are, however, several
arguments that sex-hormone-binding glo-
bulin did not interfere in our assay for the
receptors. The electrophoresis technique is
the only procedure currently available
which'separates distinctly specific receptor
proteins and sex-hormone-binding globu-
lins, in fact the method allows the separate
determination of sex-hormone-binding
globulin (Wagner & Rtiffert, 1974). Our
electrophoretic diagrams obtained with
the Wagner technique conformed to those
published by various investigators (Wag-
ner, 1972; Krieg et al., 1974; Wagner &
Jungblut, 1976a,b; Trams & Maass, 1977).
Moreover, the correlation between the
results obtained with the electrophoretic
method and the charcoal method for
oestrogen receptor is excellent (Korsten &
Persijn, 1977).
In 11 cases there was measurable DHT-
binding activity. The higher levels above
5 fmol/mg tissue cytosol were found in 4
men and one woman, the latter having the
highest level. Also DHT binding activity
was not related to the state ofthe disease,
nor to the age and sex of the patients.
Two young male patients with advanced
disease received anti-testosterone treat-
ment, and one also received ethinyl
oestradiol in high doses. However, these
treatments had no effect on the progression
of the disease. The dose of the anti-
androgens may have been too low or the
treatment too short, but it may also be
thatthefraction ofmelanoma cellswithout
receptor was too large, and it may also be
that proliferation of the cells in spite of
the presence of a receptor does not require
the stimulus of the appropriate hormones.
Recently also, Fisher et al. (1978) showed
that the presence of £2 receptor did not
correlate with the response on the admin-
istration of diethylstilboestrol, which oc-
curred only in 2 patients, both having no
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E2-binding activity, while 4/18 patients
with E2 receptor in metastases did not
respond.
It canthereforetentatively be concluded
that receptor determinations are of no
help in the management of patients with
advanced malignant melanoma.
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